Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Integer Holdings Corporation (ITGR) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Devices
$90.20
+1.83 (2.07%)Did ITGR Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Integer is one of their latest high-conviction picks.
Based on our analysis of 13 Wall Street analysts, ITGR has a neutral consensus with a median price target of $93.50 (ranging from $84.00 to $101.00). The overall analyst rating is Buy (7.6/10). Currently trading at $90.20, the median forecast implies a 3.7% upside. This outlook is supported by 5 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Nathan Treybeck at Wells Fargo, suggesting a 6.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for ITGR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 20, 2026 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $84.00 |
| Feb 20, 2026 | Benchmark | Robert Wasserman | Buy | Upgrade | $95.00 |
| Feb 20, 2026 | Truist Securities | Richard Newitter | Buy | Maintains | $97.00 |
| Feb 20, 2026 | Citigroup | Joanne Wuensch | Neutral | Maintains | $92.00 |
| Dec 18, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $95.00 |
| Dec 11, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $75.00 |
| Nov 24, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $86.00 |
| Nov 3, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $69.00 |
| Oct 24, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $95.00 |
| Oct 24, 2025 | Wells Fargo | Nathan Treybeck | Equal-Weight | Downgrade | $80.00 |
| Oct 24, 2025 | Citigroup | Joanne Wuensch | Neutral | Downgrade | $77.00 |
| Oct 24, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $88.00 |
| Oct 24, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $93.00 |
| Oct 24, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $82.00 |
| Oct 24, 2025 | Benchmark | Robert Wasserman | Hold | Downgrade | $N/A |
| Oct 21, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $133.00 |
| Oct 15, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $121.00 |
| Jul 25, 2025 | Raymond James | Andrew Cooper | Outperform | Maintains | $143.00 |
| Jul 25, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $137.00 |
| Jul 25, 2025 | Wells Fargo | Nathan Treybeck | Overweight | Maintains | $132.00 |
The following stocks are similar to Integer based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Integer Holdings Corporation has a market capitalization of $3.10B with a P/E ratio of 30.6x. The company generates $1.85B in trailing twelve-month revenue with a 5.5% profit margin.
Revenue growth is +5.0% quarter-over-quarter, while maintaining an operating margin of +12.8% and return on equity of +6.1%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Provides advanced medical device solutions.
The company designs, develops, and manufactures complex medical devices and components for various markets, including cardiovascular and orthopedic. It generates revenue by partnering with medical device original equipment manufacturers (OEMs) to support innovation and scale in the medical technology sector.
Integer Holdings has a strong market presence with substantial capitalization and diversified revenue streams, indicating robust financial health. Its commitment to quality and innovation positions it as a key player in advancing patient care through next-generation technology.
Healthcare
Medical Devices
11,000
Mr. Payman Khales
United States
2000
Integer Holdings Corporation's Chair, Pamela G. Bailey, will not seek re-election at the 2026 Annual Meeting on May 20, 2026.
Pamela G. Bailey's decision not to seek re-election may signal potential changes in leadership strategy, impacting investor confidence and future corporate direction at Integer Holdings.
Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, offering a systematic approach to stock selection.
The Zacks Style Scores provide a streamlined method for identifying high-potential stocks, aiding investors in making informed, style-aligned investment decisions.
Integer Holdings Corporation (NYSE: ITGR) will host a conference call on April 30, 2026, at 8 a.m. CT to discuss Q1 financial results and business highlights.
Integer Holdings' upcoming Q1 earnings call may reveal key financial performance indicators and strategic insights, impacting stock valuation and investor sentiment in the medical device sector.
Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, providing a tool for informed stock selection.
Zacks Style Scores provide a streamlined method to identify high-potential stocks, enhancing investment decision-making and potentially improving portfolio performance.
An Integer insider sold 825 shares for $70,000 on March 13, 2026, representing 15.85% of their direct common stockholdings.
Insider selling 15.85% of their holdings may signal lack of confidence in the company, potentially affecting stock price and investor sentiment.
ITGR shows strong product sales and R&D growth, but faces near-term risks from product adoption delays and margin pressures.
ITGR's robust sales and R&D suggest potential growth; however, delays in product adoption and margin pressures may hinder short-term performance, impacting investor sentiment and stock valuation.
Based on our analysis of 13 Wall Street analysts, Integer Holdings Corporation (ITGR) has a median price target of $93.50. The highest price target is $101.00 and the lowest is $84.00.
According to current analyst ratings, ITGR has 5 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $90.20. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict ITGR stock could reach $93.50 in the next 12 months. This represents a 3.7% increase from the current price of $90.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
The company designs, develops, and manufactures complex medical devices and components for various markets, including cardiovascular and orthopedic. It generates revenue by partnering with medical device original equipment manufacturers (OEMs) to support innovation and scale in the medical technology sector.
The highest price target for ITGR is $101.00 from at , which represents a 12.0% increase from the current price of $90.20.
The lowest price target for ITGR is $84.00 from Nathan Treybeck at Wells Fargo, which represents a -6.9% decrease from the current price of $90.20.
The overall analyst consensus for ITGR is neutral. Out of 13 Wall Street analysts, 5 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $93.50.
Stock price projections, including those for Integer Holdings Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.